• limited stage SCLC (ls-SCLC)
• limited stage SCLC (ls-SCLC) - maintenance (M) 1
• limited stage SCLC (ls-SCLC) - 2nd Line (L2)
• melanoma (ML)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• Ipilimumab (10 mg/kg)
• ipilimumab plus gp100
• ipilimumab plus SoC
• tremelimumab
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus cometinib
• atezolizumab plus SoC
• nivolumab based treatment
• nivolumab alone
• nivolumab followed by ipilimumab
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (10mg/kg) 2 weeks
• pembrolizumab (2mg/kg)
• pembrolizumab plus SoC
• Immune checkpoint association
• nivolumab plus ipilimumab
• relatlimab plus nivolumab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs alkylating agents
• vs dacarbazine
• vs fotemustine
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs immune chekpoint inhibitors
• vs anti-CTLA-4
• vs ipilimumab based treatment
• vs ipilimumab alone
• vs Ipilimumab (10 mg/kg)
• vs ipilimumab plus dacarbazine
• vs ipilimumab followed by nivolumab
• vs anti-PD-(L)1
• vs nivolumab based treatment
• vs nivolumab alone
• vs pembrolizumab based treatment
• vs pembrolizumab alone
• vs Immune checkpoint association
• vs nivolumab plus ipilimumab
• vs Immunostimulant
• vs interferon alpha
• vs vaccine
• vs gp100
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  mML - L1 - BRAF mutant;